Last reviewed · How we verify
Group C:TDF and Peginterferon alfa-2a then TDF — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Group C:TDF and Peginterferon alfa-2a then TDF (Group C:TDF and Peginterferon alfa-2a then TDF) — Ruijin Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Group C:TDF and Peginterferon alfa-2a then TDF TARGET | Group C:TDF and Peginterferon alfa-2a then TDF | Ruijin Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Group C:TDF and Peginterferon alfa-2a then TDF CI watch — RSS
- Group C:TDF and Peginterferon alfa-2a then TDF CI watch — Atom
- Group C:TDF and Peginterferon alfa-2a then TDF CI watch — JSON
- Group C:TDF and Peginterferon alfa-2a then TDF alone — RSS
Cite this brief
Drug Landscape (2026). Group C:TDF and Peginterferon alfa-2a then TDF — Competitive Intelligence Brief. https://druglandscape.com/ci/group-c-tdf-and-peginterferon-alfa-2a-then-tdf. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab